Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...
The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...
Reports Q4 revenue EUR 173.92M vs. EUR 137.7M last year. “Having achieved pivotal milestones in 2024, Ascendis is positioned to continue strong ...
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
COPENHAGEN - Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company valued at $7.15 billion, has initiated a share ...
Ascendis Pharma (ASND) reported its fourth-quarter 2024 earnings, highlighting a significant revenue increase and a positive market reaction. The company posted total revenue of €173.9 million for the ...
Pepto-Bismol (bismuth salicylate) and Tums (calcium carbonate) are both over-the-counter (OTC) medications for heartburn and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback